A randomized male tolerance study of dapivirine gel following multiple topical penile exposures (MTN 012/IPM 010)

AIDS Research and Human Retroviruses

Volumn 30, Issue 2, 2014, Pages 184-189

  Cranston, Ross D ^a   Hoesley, Craig ^b   Carballo Diéguez, Alex ^c   Hendrix, Craig W ^d   Husnik, Marla ^e   Levy, Lisa ^f   Hall, Wayne ^g   Soto Torres, Lydia ^h   Nel, Annalene M ⁱ  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c HIV Center for Clinical and Behavioral Studies   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Statistical Center for HIV/AIDS Research and Prevention   (United States)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g Microbicide Trials Network   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DAPIVIRINE; LUBRICATING AGENT; PLACEBO;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PARESTHESIA; APPLICATION SITE PRURITUS; APPLICATION SITE SWELLING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CIRCUMCISION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERANCE; GEL; HETEROSEXUALITY; HOMOSEXUALITY; HUMAN; HUMAN EXPERIMENT; IC 50; LGBT PEOPLE; LIMIT OF QUANTITATION; MALE; NORMAL HUMAN; ONE-NIGHT STAND; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEBACEOUS GLAND DISEASE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; TIME;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHEMOPREVENTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GELS; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; PLACEBOS; PLASMA; PYRIMIDINES; QUESTIONNAIRES; YOUNG ADULT;

EID: 84893442169     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0170     Document Type: Article

References (11)

1. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al.: Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009;51(4):416-423.
2. Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al.: Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010;26(11):1181-1190.
3. Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, et al.: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009;23(12):1531-1538.
4. Nel AM, Smythe SC, Habibi S, Kaptur PE, and Romano JW: Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010;55(2):161-169.
5. Carballo-Dieguez A, Balan IC, Morrow K, Rosen R, Mantell JE, Gai F, et al.: Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050). AIDS Care 2007;19(8):1026-1031.
6. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, and Callahan MM: Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS 2009;20(6):384-386.
7. Mauck C, Frezieres R, Walsh T, Robergeau K, and Callahan M: Cellulose sulfate: Tolerance and acceptability of penile application. Contraception 2001;64(6):377-381.
8. Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, et al.: Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr 2003;33(4):476-483.
9. Mauck CK, Frezieres RG, Walsh TL, Schmitz SW, Callahan MM, and Bax R: Male tolerance study of 1% C31G. Contraception 2004;70(3):221-225.
10. Schwartz JL, Poindexter A, Schmitz SW, Mauck C, and Callahan MM: Male tolerance of ACIDFORM gel. Contraception 2005;71(6):443-446.
11. Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF, et al.: Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007; 75(2):136-141.